Selenexer: Bridging Therapy in Myeloma

This chapter explores the drug Selenexer as a bridging therapy to enhance T-cell performance in myeloma treatment. It discusses trial findings on dosage impacts, patient management strategies, and emerging therapies aimed at improving treatment outcomes for resistant patients.